Nivolumab Plus Ipilimumab Remains First-Line Standard for Unresectable Mesothelioma

FDA-Backed Immunotherapy Combination Continues to Reshape Mesothelioma Treatment Landscape

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) remains the gold standard first-line treatment for patients with unresectable malignant pleural mesothelioma, marking a historic shift away from decades of chemotherapy-only protocols. First approved by the U.S. Food and Drug Administration in October 2020 based on the landmark CheckMate 743 clinical trial, this dual immunotherapy regimen has continued to demonstrate durable survival benefits in updated analyses through 2025 and into 2026. For the estimated 3,000 Americans diagnosed with mesothelioma each year, the availability of an immunotherapy option represents the most significant therapeutic advancement in nearly two decades — since the 2004 approval of pemetrexed plus cisplatin. The latest data presented at major oncology conferences confirms that nivolumab plus ipilimumab not only extends overall survival compared to chemotherapy but offers particular advantages for patients with non-epithelioid tumor subtypes, a population historically considered to have the poorest prognosis. This article examines the full scope of the clinical evidence, patient eligibility, side effects, cost considerations, and emerging biomarker research that may further refine patient selection.

The CheckMate 743 Trial: Design, Results, and Long-Term Follow-Up

The CheckMate 743 trial (NCT02899299) was a Phase III, randomized, open-label, multicenter study that enrolled 605 patients with previously untreated, unresectable malignant pleural mesothelioma between November 2016 and April 2018. Patients were randomized 1:1 to receive either nivolumab (3 mg/kg every two weeks) plus ipilimumab (1 mg/kg every six weeks) for up to two years, or standard chemotherapy with pemetrexed plus cisplatin or carboplatin for up to six cycles. The primary endpoint was overall survival (OS), with secondary endpoints including objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR).

The initial results, published in The Lancet in January 2021, demonstrated a statistically significant improvement in median overall survival: 18.1 months for the immunotherapy combination versus 14.1 months for chemotherapy (hazard ratio 0.74; 95% CI, 0.60-0.91; p = 0.0020). This 4-month improvement in median survival, while seemingly modest in absolute terms, translated to a 26% reduction in the risk of death — a clinically meaningful benefit in a disease where historical median survival rarely exceeded 12 months.

Updated analyses presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting with a minimum follow-up of three years confirmed the durability of the survival benefit. The 3-year overall survival rate was 23.2% for nivolumab plus ipilimumab compared to 15.4% for chemotherapy. At the four-year landmark analysis presented at the 2023 World Conference on Lung Cancer (WCLC), approximately 1 in 5 patients in the immunotherapy arm remained alive, compared to roughly 1 in 10 in the chemotherapy arm.

The objective response rate was 39.6% for nivolumab plus ipilimumab versus 44.0% for chemotherapy. While the ORR was numerically lower for immunotherapy, the median duration of response was substantially longer: 11.0 months for immunotherapy versus 6.7 months for chemotherapy. This finding underscores a key principle of immunotherapy — responses, once achieved, tend to be more durable than those seen with cytotoxic chemotherapy.

Perhaps the most clinically significant finding from CheckMate 743 was the pronounced benefit in patients with non-epithelioid histology (biphasic and sarcomatoid subtypes). In this subgroup, median OS was 18.1 months with immunotherapy versus 8.8 months with chemotherapy (HR 0.46; 95% CI, 0.31-0.68), representing a 54% reduction in the risk of death. For patients with epithelioid histology, the benefit was more modest (18.7 vs. 16.5 months; HR 0.86), though trends still favored immunotherapy.

Progression-Free Survival and Disease Control

Median PFS was 6.8 months for nivolumab plus ipilimumab versus 7.2 months for chemotherapy. The similar PFS despite superior OS reflects the unique kinetics of immunotherapy, where some patients experience initial pseudo-progression or delayed responses that ultimately translate into long-term survival benefits. The disease control rate (complete response + partial response + stable disease) was 77% for the immunotherapy arm.

Key Data at a Glance

Tumor Subtype Analysis and Biomarker Research

Mesothelioma is classified into three primary histological subtypes: epithelioid (approximately 60-70% of cases), biphasic (20-30%), and sarcomatoid (10-15%). Historically, sarcomatoid and biphasic mesothelioma have carried significantly worse prognoses, with median survival often below 8 months with chemotherapy alone.

The dramatic benefit of nivolumab plus ipilimumab in non-epithelioid mesothelioma has fundamentally changed clinical practice for these patients. Before this trial, there was no standard treatment that meaningfully extended survival for sarcomatoid mesothelioma. The hazard ratio of 0.46 in the non-epithelioid subgroup is one of the most striking treatment effects observed in any mesothelioma trial.

PD-L1 Expression: Exploratory analyses from CheckMate 743 examined programmed death-ligand 1 (PD-L1) expression as a potential biomarker. Patients with PD-L1 expression of 1% or higher appeared to derive greater benefit from immunotherapy (HR 0.69) compared to those with PD-L1 below 1% (HR 0.94). However, PD-L1 expression is not currently required for treatment eligibility, as benefits were observed across all PD-L1 subgroups.

Tumor Mutational Burden (TMB): Emerging research is evaluating TMB as a complementary biomarker. Higher TMB has been associated with improved responses to immune checkpoint inhibitors across multiple tumor types. Preliminary data suggest that mesothelioma patients with higher TMB may derive enhanced benefit from nivolumab plus ipilimumab, though prospective validation is needed.

BAP1 Mutations: Approximately 60% of mesothelioma tumors harbor mutations in the BAP1 gene. Research is actively investigating whether BAP1 mutation status influences response to immunotherapy. Early data suggest that BAP1-mutant tumors may have distinct immune microenvironments that could affect treatment outcomes.

Circulating Tumor DNA (ctDNA): Liquid biopsy approaches measuring ctDNA are being explored as tools for monitoring treatment response and detecting resistance. Studies presented at the 2025 ASCO Annual Meeting demonstrated that ctDNA dynamics during the first 8 weeks of immunotherapy correlated with eventual treatment outcomes in mesothelioma patients.

Side Effect Profile and Quality of Life Considerations

Understanding the toxicity profile of nivolumab plus ipilimumab is essential for informed treatment decision-making. As with all immune checkpoint inhibitor combinations, this regimen carries the risk of immune-related adverse events (irAEs) — side effects caused by an overactive immune system attacking healthy tissues.

In CheckMate 743, treatment-related adverse events of any grade occurred in 79.1% of patients receiving nivolumab plus ipilimumab, compared to 81.9% of patients receiving chemotherapy. Grade 3 or 4 events (serious side effects) occurred in 30.7% versus 32.0%, respectively. While the overall rates of serious adverse events were similar between the two arms, the types of side effects differed significantly.

Common immune-related adverse events include:

• Skin reactions: Rash, pruritus (itching), and vitiligo occurred in approximately 25-30% of patients. Most cases were mild to moderate (Grade 1-2).
• Endocrine disorders: Hypothyroidism (12%), hyperthyroidism (5%), and adrenal insufficiency (2-3%) were observed. Endocrine irAEs often require lifelong hormone replacement.
• Gastrointestinal: Diarrhea and colitis occurred in approximately 15-20% of patients. Severe colitis (Grade 3+) required corticosteroid treatment and occasionally immunosuppression.
• Hepatotoxicity: Elevated liver enzymes (hepatitis) occurred in approximately 10-15% of patients, with 5-7% experiencing Grade 3+ hepatitis.
• Pneumonitis: Immune-mediated lung inflammation occurred in 3-5% of patients. This is of particular concern in mesothelioma patients who may already have compromised lung function.
• Nephritis: Kidney inflammation occurred in 2-3% of patients.

Treatment was discontinued due to adverse events in 23.2% of patients in the immunotherapy arm versus 16.3% in the chemotherapy arm. Importantly, some patients who discontinued treatment due to irAEs still experienced durable responses, suggesting that even abbreviated courses of immunotherapy can provide lasting benefit.

Quality of life analyses from CheckMate 743, published in The Lancet Oncology, demonstrated that patients receiving nivolumab plus ipilimumab maintained or improved their quality of life during treatment, while chemotherapy-treated patients experienced a decline. Time to deterioration of symptoms was significantly longer in the immunotherapy arm.

Patient Eligibility and Access Considerations

Who is eligible for nivolumab plus ipilimumab?

The FDA approval covers adult patients with unresectable malignant pleural mesothelioma who have not received prior systemic therapy. Key eligibility criteria based on the CheckMate 743 protocol include:

• Histologically confirmed malignant pleural mesothelioma (any subtype)
• Disease considered unresectable by a thoracic surgeon or multidisciplinary tumor board
• No prior systemic anticancer therapy for mesothelioma
• ECOG performance status of 0 or 1 (able to perform most daily activities)
• Adequate organ function (liver, kidney, bone marrow)
• No active autoimmune disease requiring systemic immunosuppression
• No prior organ transplant

Patients who have undergone prior surgery (including extrapleural pneumonectomy or pleurectomy/decortication) with disease recurrence may still be eligible, provided they have not received systemic chemotherapy.

Insurance Coverage and Financial Assistance:

The combined cost of nivolumab and ipilimumab can exceed $150,000 per year, making insurance coverage a critical consideration. The following coverage pathways exist:

• Medicare: Covers FDA-approved indications under Part B (physician-administered drugs)
• Commercial Insurance: Most major insurers cover the combination based on FDA approval and NCCN guideline inclusion
• VA Healthcare: The Department of Veterans Affairs covers immunotherapy for eligible veterans, an important consideration given the high incidence of mesothelioma among military veterans
• Patient Assistance Programs: Bristol-Myers Squibb offers the BMS Access Support program, providing free medication to eligible uninsured or underinsured patients
• Asbestos Trust Funds: Compensation from asbestos trust fund claims can help offset out-of-pocket medical costs

What This Means for Patients and Families

If you or a loved one has been diagnosed with unresectable malignant pleural mesothelioma, the availability of nivolumab plus ipilimumab represents a meaningful advance in treatment options. Here are key considerations:

Start the conversation early. Discuss immunotherapy with your oncologist at the time of diagnosis. Since nivolumab plus ipilimumab is approved as first-line therapy, the treatment decision needs to be made before starting any systemic treatment.

Seek specialized care. Mesothelioma is a rare cancer, and outcomes are generally better when treatment is managed by physicians experienced with this disease. Major cancer centers with dedicated mesothelioma programs can offer clinical trial access and multidisciplinary expertise.

Understand the side effect profile. Immunotherapy side effects differ fundamentally from chemotherapy side effects. While you may avoid nausea, hair loss, and severe fatigue common with chemo, immune-related side effects require vigilant monitoring. Report any new symptoms promptly to your care team.

Explore legal options simultaneously. A mesothelioma diagnosis resulting from asbestos exposure may entitle you to significant compensation. Pursuing legal options does not interfere with medical treatment and can provide crucial financial resources during a difficult time.

Expert Legal Perspective

"The approval of nivolumab plus ipilimumab has changed the landscape not only for mesothelioma treatment but also for legal claims. Patients who are diagnosed today have access to treatments that can extend their lives meaningfully, which in turn affects the calculation of damages in asbestos litigation. Extended survival means additional medical costs, but it also means more time with family — something that juries understand deeply. We encourage every diagnosed patient to explore both their treatment options and their legal rights simultaneously, because compensation from asbestos trust funds and lawsuits can help cover the significant costs of immunotherapy treatment."

>

— Paul Danziger, Managing Partner, Danziger & De Llano, LLP

Patients should be aware that a mesothelioma diagnosis resulting from asbestos exposure may entitle them to compensation through asbestos trust funds, personal injury lawsuits, or VA benefits. These legal avenues exist independently of treatment decisions and can provide financial resources to cover medical expenses, lost income, and other damages.

Related Resources

• Mesothelioma Overview — comprehensive guide to types, stages, and prognosis
• Diagnosis & Treatment Guide — detailed information on diagnostic procedures and treatment options
• Compensation Options — explore trust funds, lawsuits, and VA claims
• Trust Fund Checker Tool — see which asbestos trust funds you may be eligible to file with
• Mesothelioma Encyclopedia — A-to-Z reference of medical and legal terms
• Treatment Centers Directory — find specialized mesothelioma treatment centers near you

Sources

1. Baas, P., et al. "First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial." The Lancet, vol. 397, no. 10272, 2021, pp. 375-386. https://doi.org/10.1016/S0140-6736(20)32714-8
2. Scherpereel, A., et al. "Three-year survival update from the CheckMate 743 trial." Journal of Clinical Oncology, vol. 40, suppl. 16, 2022, abstract 8507. https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.8507
3. U.S. Food and Drug Administration. "FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma." October 2, 2020. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma
4. Peters, S., et al. "Quality of life in patients with unresectable pleural mesothelioma treated with nivolumab plus ipilimumab." The Lancet Oncology, vol. 23, no. 8, 2022, pp. 1031-1042. https://doi.org/10.1016/S1470-2045(22)00290-4
5. National Comprehensive Cancer Network (NCCN). "Clinical Practice Guidelines in Oncology: Malignant Pleural Mesothelioma, Version 1.2026." https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1471
6. American Cancer Society. "Key Statistics About Malignant Mesothelioma." Updated January 2026. https://www.cancer.org/cancer/types/malignant-mesothelioma/about/key-statistics.html
7. Fennell, D.A., et al. "Tumor mutational burden as a biomarker for immunotherapy in malignant pleural mesothelioma." Journal of Thoracic Oncology, vol. 18, no. 5, 2023, pp. 612-621. https://doi.org/10.1016/j.jtho.2023.01.014
8. Bristol-Myers Squibb. "Opdivo + Yervoy Prescribing Information." Revised 2025. https://packageinserts.bms.com/pi/pi_opdivo.pdf